Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Jun 29, 2023 1:13pm
565 Views
Post# 35520777

What is important & what is not

What is important & what is notOnc is within a whisker of announcing a phase 3 entry/ deal with Pancreatic cancer.
They were invited & sponsored by PanCan.
That is important.
Assuming they go the partnership/ licensing deal, that would elevate not only the SP. well into the $15 range, it would also increase the corporate value in general.
That is important.
Yes, they have been using the ATM, to fund operations.
I can't prove how many shares.....don't care.... that is not important.
The only time total share count matters is it/ when a company buyout takes place.
Right now. If you go on oncolytics biotech web site they list shares as of last quarter.
presently assuming 70million shares which is what they have posted as of May 8th.
that equates to $14.28/ps/ billion$$.
Assuming the .buyout is $3-$5 billion, as a few have mentioned, the SP, becomes $42-  $70 range
Adding an addional 5 million shares. Would move those numbers down a whopping .80/ share on a billion buyout.
I could go in with mutiple scenarios.Take away.
In the last year;Onc has not doubled their share count.
however with now 2 phase two ready opportunities, has easy doubled the business value of the company.
The share count only matters on a buy- out.
To me a red- herring distraction.....not important.
The upcoming " deal" with panc phase 3 is important.
They said final information within 90 days.
That is very important 
They also post cash flow runway well into next year....That is important.
Gives them negotiating strength.



<< Previous
Bullboard Posts
Next >>